Allogeneic stem-cell transplantation in renal-cell carcinoma.
Metastatic renal-cell carcinoma (RCC) remains resistant to nearly all standard cytotoxic therapies, but immune-based cytokine therapies benefit a small minority of patients with advanced RCC. Nonmyeloablative allogeneic stem-cell transplantation is a novel approach to harnessing the immune system to combat this cancer. The strategy relies on a T-cell graft-versus-malignancy effect mediated by donor T cells. Preliminary work in using nonmyeloablative allogeneic stem-cell transplant in RCC has identified a graft-versus-RCC effect and yielded encouraging clinical responses.
Hayes-Lattin
B M
BM
Division of Hematology and Medical Oncology, Oregon Health Sciences University, Mail Code L586, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA.
Maziarz
R T
RT
Beer
T M
TM
D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007167:Immunotherapy; D007680:Kidney Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D014184:Transplantation, Homologous / Q000276:immunology